Deals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates
AbbVieBrise Pharmaceuticals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

Brise Pharmaceuticals Co. Ltd., a portfolio company of Sherpa Healthcare Partners, announced an update on its exclusive license agreement with AbbVie (NYSE: ABBV), originally entered into in 2024. Under the…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline
KYinno Biotechnology

Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline

Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing
Cell-therapyCellular Origins

Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing

Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline
BiotechHanx Biopharmaceuticals

Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
Everest MedicinesHasten Biopharmaceutical

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Show More